How should I evaluate and manage an elderly patient with anemia and thrombocytopenia?

Evaluation and Management of Elderly Patients with Anemia and Thrombocytopenia

In elderly patients presenting with both low hemoglobin and low platelets, immediately pursue bone marrow evaluation with cytogenetic analysis to exclude myelodysplastic syndrome (MDS), which is the most critical diagnosis to identify given its higher incidence in this age group and fundamentally different treatment approach. 1

Initial Diagnostic Approach

Essential Laboratory Evaluation

• Obtain complete blood count with differential, peripheral blood smear examination, and assess all three cell lines (RBC, WBC, platelets) simultaneously to determine if bicytopenia or pancytopenia is present. 2

• Examine the peripheral blood smear for morphologic features including macrocytosis, dysplastic changes, or blast cells that suggest MDS versus other causes. 2

• Perform cytogenetic analysis and bone marrow biopsy as this is essential for diagnosing MDS and risk stratification using the Revised International Prognostic Scoring System (IPSS-R). 1

Critical Differential Diagnoses to Exclude

• Rule out myelodysplastic syndrome first, as MDS incidence increases with age and presents with cytopenias; the rate of MDS evolution is significantly higher in elderly patients (12% versus 7% in younger patients). 3

• Exclude drug-induced thrombocytopenia by reviewing all medications, as elderly patients typically receive multiple drugs and many can cause thrombocytopenia. 2

• Consider aplastic anemia, though elderly patients show significantly lower overall response to first-line therapy (47% versus 65% in younger patients) and higher mortality. 3

• Assess for secondary causes including nutritional deficiencies (B12, folate, iron), chronic kidney disease, liver disease, and autoimmune conditions. 4

Management Based on Diagnosis

If MDS is Diagnosed

Lower-Risk MDS

• Initiate erythropoiesis-stimulating agents (ESAs) as first-line therapy if serum erythropoietin level is ≤500 mU/mL to address anemia. 1

• For del(5q) MDS with anemia, use lenalidomide as Category 1 preferred treatment per NCCN guidelines. 1

• When anemia persists after ESA failure in MDS with ring sideroblasts, administer luspatercept. 1

• For thrombocytopenia with <5% marrow blasts, consider thrombopoietin-receptor agonists (romiplostim or eltrombopag), though be aware these are not approved in Europe and carry thrombotic risk in elderly patients. 1, 5

• Avoid thrombopoietin-receptor agonists if >5% blasts are present, as this increases risk of blast proliferation and transformation to acute myeloid leukemia. 1

Higher-Risk MDS

• Start hypomethylating agents (azacitidine or decitabine) immediately, as these improve survival and are first-line therapy for higher-risk MDS. 1

• Refer for allogeneic hematopoietic stem-cell transplantation evaluation, as this is the only curative option, though recognize that elderly patients have higher transplant-related mortality (41% died in second-line transplant, mainly from complications). 1, 3

If Aplastic Anemia is Diagnosed

• Recognize that older age is the main factor associated with mortality (HR 1.64, p<0.001), followed by disease severity and male gender. 3

• For younger elderly patients (<70 years) with severe aplastic anemia, use equine antithymocyte globulin (ATG) with or without cyclosporine A as recommended first-line therapy. 1

• Consider early allogeneic stem-cell transplantation for fit elderly patients with matched donors, though understand that 41% mortality rate exists with transplant complications in this age group. 3

• For patients <60 years with <5% blasts, hypocellular marrow, or PNH clone, consider immunosuppressive therapy (antithymocyte globulin ± cyclosporine). 1

If Immune Thrombocytopenia (ITP) is Diagnosed

• Use short courses of corticosteroids as first-line treatment, but avoid prolonged steroid therapy given higher risk of toxic effects in elderly patients. 6, 5

• Reserve intravenous immunoglobulin for patients with severe bleeding complications, as IVIg may lead to renal failure in elderly patients. 5

• Prefer thrombopoietin receptor agonists as second-line treatment given their good efficacy/tolerance ratio, though thrombotic risk is increased in older people. 6, 5

• Alternative second-line options include rituximab (avoid if history of infection or hypogammaglobulinemia), dapsone, fostamatinib, or immunosuppressive drugs depending on comorbidities. 6, 5

• Splenectomy is less effective in elderly patients and carries increased thrombosis risk, so reserve for fit patients with chronic refractory disease. 6, 5

Supportive Care Measures

Transfusion Thresholds

• Maintain hemoglobin ≥8 g/dL, or 9-10 g/dL in patients with cardiovascular comorbidities, through red cell transfusion. 1, 4

• Do not routinely give prophylactic platelet transfusions except for active bleeding or before invasive procedures. 1

• Avoid under-transfusion below recommended hemoglobin thresholds, as this compromises quality of life. 1

Iron Overload Management

• Strongly recommend iron chelation therapy for transplant candidates with iron overload. 1

• Consider chelation after 20-60 red-cell units transfused or ferritin >1,000-2,500 µg/L in lower-risk MDS with favorable prognosis. 1

• Perform cardiac magnetic resonance T2 imaging in heavily transfused patients (>70-80 units)* to monitor cardiac iron. 1

Infection Prevention

• Administer prompt broad-spectrum antibiotics for febrile neutropenia, but do not use routine prophylactic antibiotics. 1

• Use short-course G-CSF during severe infections in neutropenic patients. 1

Mandatory Hematology Referral Criteria

• Refer immediately when MDS, leukemia, or lymphoma is suspected based on cytogenetic analysis or bone marrow findings. 1

• Refer promptly for aplastic anemia requiring immunosuppressive therapy or transplant evaluation. 1

• Refer for refractory pancytopenia despite treatment of reversible causes. 1

• Refer when patients require advanced therapies including hypomethylating agents, targeted agents, or cellular therapy. 1

Critical Pitfalls to Avoid

• Inadequate cytogenetic analysis leads to missed or incorrect MDS diagnosis and risk stratification, which is particularly problematic given the 12% MDS evolution rate in elderly patients with cytopenias. 1, 3

• Do not assume immune thrombocytopenia without excluding MDS, as diagnostic work-up must rule out myelodysplastic syndrome in elderly patients with thrombocytopenia. 6

• Recognize that elderly patients have inferior outcomes even with modern therapies, with older age remaining the main mortality factor (HR 1.64) independent of treatment modality. 3

• Account for increased bleeding, thrombotic, and infectious disease risks when making treatment decisions, and consider all comorbidities and concomitant medications including anticoagulants. 6, 5